As some adopt a wait-and-see attitude to the company's new multiple sclerosis drug Tysabri (natalizumab, formerly Antegren), Biogen Idec Inc. reported satisfying fourth-quarter 2004 earnings and offered guidance for the coming year near the top end of consensus estimates. (BioWorld Today)
When company officials from Northwest Biotherapeutics Inc. met with would-be financiers from Toucan Capital II LP at 2004's JPMorgan Healthcare Conference, NBI was "quite literally a week from closing its doors," recalled Alton Boynton, president, chief operating officer and co-founder of NBI.
Following last summer's go-ahead for its Phase III trial of PolyHeme, a hemoglobin-based oxygen carrier for hemorrhagic shock brought about by severe injury, Northfield Laboratories Inc. has priced an offering of 4.5 million shares at $15 each, for gross proceeds of about $67.5 million. (BioWorld Today)
About this time last year, Xcel Pharmaceuticals Inc. bought the rights to the Phase III-ready epilepsy drug retigabine from Viatris GmbH and Co., of Frankfurt, Germany. (BioWorld Today)
Proving its financial mettle even without the hoped-for larger alfimeprase deal with Amgen Inc., Nuvelo Inc. priced an offering of 8.5 million shares at $7.50 each to pull down $63.75 million. (BioWorld Today)
